OmniAb, Inc. - Warrant (OABIW)

On our desk, OABIW has been a fascinating high-beta vehicle to track following the Q1 2026 filings. While institutional investors have established positions representing meaningful capital locks—mitigating some of the retail panic-selling vulnerability—the broader macroeconomic sentiment around low-priced warrants remains exceptionally cautious. Looking at the capital flow data, you see a delicate tug-of-war between fundamental believers tracking their 107 active partners and macro traders treating the warrant like a pure option decay play.

Analyzing the fundamental metrics retrieved from SEC filings reveals a stark mismatch between operating scale and profitability. OmniAb boasts impressive topline exposure with over 400 active research programs utilizing its Biological Intelligence platform, but the TTM net profit margin sits at a staggering -347.0% alongside negative EPS of -$0.57. For warrant holders like OABIW, this fundamental cash burn profile means that any macro-induced liquidity crunch could completely wipe out leveraged equity options regardless of technological milestones.

From a technical and clinical screening standpoint, our lab focuses heavily on whether discovery-stage platforms can translate partner programs into durable commercial milestones. OmniAb's technology platform enables rapid screening of diverse antibody repertoires, which is fundamentally sound and clearly attracts big pharma collaborators. However, when evaluating derivative instruments like OABIW, researchers must separate the scientific viability of the underlying antibody discovery engine from the brutal math of warrant expiration timelines and structural negative returns.